{"contentid": 488533, "importid": NaN, "name": "Pfizer adds $3.5 billion in first-quarter vaccine sales", "introduction": "Sales of Comirnaty, Pfizer\u00e2\u0080\u0099s BioNTech-partnered coronavirus vaccine, led the firm to a better-than-expected first quarter, with revenues up 45% at $14.6 billion.", "content": "<p>Sales of Comirnaty, Pfizer&rsquo;s (NYSE: PFE) BioNTech-partnered (Nasdaq: BNTX) coronavirus vaccine, led the firm to a better-than-expected first quarter, with revenues up 45% at $14.6 billion.</p>\n<p>Following Generally Accepted Accounting Principles (GAAP), the firm generated $4.9 billion in net income for the first three months of the year, equivalent to 85 cents per share.</p>\n<p>The firm&rsquo;s coronavirus vaccine, also dubbed BNT162b2, which is the most widely used of all approved vaccines in the USA, added $3.5 billion in revenues. The firm now anticipates $26 billion in sales from the product this year.</p>\n<p>The experience working with BioNTech seems to have inspired a strategic shift from the New York-based pharma major, with chief executive Albert Bourla announcing plans to create more vaccines using mRNA technology.</p>\n<p>Building on the success of Comirnaty, the firm aims to compete with established vaccines giants such as GlaxoSmithKline (LSE: GSK) and Sanofi (Euronext: SAN) to become a major player in this treatment setting.</p>\n<h2>Strong financials</h2>\n<p>Pfizer&rsquo;s work in combating the novel coronavirus was far from the only positive note in the firm&rsquo;s first quarter financial results, which reflected a strong performance across the board.</p>\n<p>Global revenues from anticoagulant Eliquis (apixaban) were up by a quarter and sales of Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) - oral transthyretin stabilizers used to prevent heart failure - up 88%.</p>\n<p>Xeljanz (tofacitinib) revenues were also strong, coming in 18% higher on a global basis, primarily driven by 16% growth in the USA, due to higher volumes.</p>\n<p>Commenting on the results, Dr Bourla said: &ldquo;Even excluding the growth provided from BNT162b2, our revenues grew 8% operationally, which aligns with our stated goal of delivering at least a 6% compound annual growth rate through 2025.&rdquo;</p>\n<p>He added: &ldquo;In addition, we have achieved important clinical, regulatory and commercial milestones across our pipeline and portfolio while also continuing to increase our capacity to supply urgently-needed doses of BNT162b2 to the world.&rdquo;</p>\n<p>Pfizer raised its guidance ranges for 2021 revenues, to between $70.5 and $72.5 billion, up from between $59.4 and $61.4.</p>\n<h2>Selected product performance</h2>\n<p>Ibrance (palbociclib) - $1.2 billion, down 1% from $1.2 billion.</p>\n<p>Xtandi (enzalutamide) - $267 million, up 28% from $209 million.</p>\n<p>Eliquis (apixaban) - $1.6 billion, up 26% from $1.3 billion.</p>\n<p>Xeljanz (tofacitinib) - $538 million, up 19% from $451 million.</p>\n<p>Inlyta (axitinib) - $229 million, up 36% from $169 million.</p>", "date": "2021-05-04 14:30:00", "meta_title": NaN, "meta_keywords": "billion, sales, revenues, vaccine, firm, coronavirus, quarter, million, first-quarter, adds, Pfizer, vaccines, better-than-expected, BioNTech-partnered", "meta_description": "Sales of Comirnarty, Pfizer\u00e2\u0080\u0099s BioNTech-partnered coronavirus vaccine, led the firm to a better-than-expected first quarter, with revenues up 45% at $14.6 billio", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-04 14:30:13", "updated": "2021-05-04 15:24:50", "access": NaN, "url": "https://www.thepharmaletter.com/article/pfizer-adds-3-5-billion-in-first-quarter-vaccine-sales", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "pfizer_colour_new_large.png", "image2id": "pfizer_colour_new_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Autoimmune Disorders, Cardio-vascular, Oncology, Vaccines", "topic_tag": "Coronavirus, Financial, Focus On, Management, Research", "geography_tag": "USA", "company_tag": "BioNTech, Pfizer", "drug_tag": "Comirnaty, Eliquis, Ibrance, Inlyta, Xeljanz, Xtandi", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-04 14:30:00"}